This invention relates to novel 3-substituted quinuclidine derivatives, which
are found to be cholinergic ligands at the nicotinic acetylcholine receptors and
modulators of the monoamine receptors and transporters.
Due to their pharmacological profile the compounds of the invention may be useful
for the treatment of diseases or disorders as diverse as those related to the cholinergic
system of the central nervous system (CNS), the peripheral nervous system (PNS),
diseases or disorders related to smooth muscle contraction, endocrine diseases
or disorders, diseases or disorders related to neuro-degeneration, diseases or
disorders related to inflammation, pain, and withdrawal symptoms caused by the
termination of abuse of chemical substances.
